title: Do older men benefit from curative therapy of localized prostate cancer?
abstract: OBJECTIVE
  Prior decision-analytic models are based on outdated or suboptimal efficacy, patient preference, and comorbidity data. We estimated life expectancy (LE) and quality-adjusted life expectancy (QALE) associated with available treatments for localized prostate cancer in men aged >/= 65 years, adjusting for Gleason score, patient preferences, and comorbidity.
  
  
  METHODS
  We evaluated three treatments, using a decision-analytic Markov model: radical prostatectomy (RP), external beam radiotherapy (EBRT), and watchful waiting (WW). Rates of treatment complications and pretreatment incontinence and impotence were derived from published studies. We estimated treatment efficacy using three data sources: cancer registry cohort data, pooled case series, and modern radiotherapy studies. Utilities were obtained from 141 prostate cancer patients and from published studies.
  
  
  RESULTS
  For men with well-differentiated tumors and few comorbidities, potentially curative therapy (RP or EBRT) prolonged LE up to age 75 years but did not improve QALE at any age. For moderately differentiated cancers, potentially curative therapy resulted in LE and QALE gains up to age 75 years. For poorly differentiated disease, potentially curative therapy resulted in LE and QALE gains up to age 80 years. Benefits of potentially curative therapy were restricted to men with no worse than mild comorbidity. When cohort and pooled case series data were used, RP was preferred over EBRT in all groups but was comparable to modern radiotherapy.
  
  
  CONCLUSIONS
  Potentially curative therapy results in significantly improved LE and QALE for older men with few comorbidities and moderately or poorly differentiated localized prostate cancer. Age should not be a barrier to treatment in this group.
authors.affiliation: University Health Network, Room ENG-233, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4. shabbir.alibhai@uhn.on.ca.
authors.forename: Shabbir M H
authors.initials: SM
authors.lastname: Alibhai
authors.forename: Gary
authors.initials: G
authors.lastname: Naglie
authors.forename: Robert
authors.initials: R
authors.lastname: Nam
authors.forename: John
authors.initials: J
authors.lastname: Trachtenberg
authors.forename: Murray D
authors.initials: MD
authors.lastname: Krahn
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003661:Decision Support Techniques; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008390:Markov Chains; D011183:Postoperative Complications; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects; D016896:Treatment Outcome